Search research articles
Contact Us
Filters
Showing results (41-50 of 44) with videos related to
Page
of 5
Sort By:
You have reached the last page of results.
This site can display upto 44 results.
Obesity (Silver Spring, Md.)
|
May 22, 2019
Impact of Intensive Lifestyle Intervention on Neural Food Cue Reactivity: Action for Health in Diabetes Brain Ancillary Study
Kathryn Demos McDermott, Samantha E Williams, Mark A Espeland, et al.
Brain Stimulation
|
November 11, 2017
Limited output transcranial electrical stimulation (LOTES-2017): Engineering principles, regulatory statutes, and industry standards for wellness, over-the-counter, or prescription devices with low risk
Marom Bikson, Bhaskar Paneri, Andoni Mourdoukoutas, et al.
Advanced Therapeutics
|
October 10, 2022
Classical Complement Pathway Inhibition in a "Human-On-A-Chip" Model of Autoimmune Demyelinating Neuropathies
John W Rumsey, Case Lorance, Max Jackson, et al.
Clinical and Translational Science
|
June 1, 2022
Safety, pharmacokinetics and target engagement of novel RIPK1 inhibitor SAR443060 (DNL747) for neurodegenerative disorders: Randomized, placebo-controlled, double-blind phase I/Ib studies in healthy subjects and patients
Maurits F J M Vissers, Jules A A C Heuberger, Geert Jan Groeneveld, et al.
Page
of 5
Search research articles
Search
Showing results (41-50 of 44) with videos related to
Sort By:
Page
of 5
You have reached the last page of results.
This site can display upto 44 results.
Obesity (Silver Spring, Md.)
|
May 22, 2019
Impact of Intensive Lifestyle Intervention on Neural Food Cue Reactivity: Action for Health in Diabetes Brain Ancillary Study
Kathryn Demos McDermott, Samantha E Williams, Mark A Espeland, et al.
Brain Stimulation
|
November 11, 2017
Limited output transcranial electrical stimulation (LOTES-2017): Engineering principles, regulatory statutes, and industry standards for wellness, over-the-counter, or prescription devices with low risk
Marom Bikson, Bhaskar Paneri, Andoni Mourdoukoutas, et al.
Advanced Therapeutics
|
October 10, 2022
Classical Complement Pathway Inhibition in a "Human-On-A-Chip" Model of Autoimmune Demyelinating Neuropathies
John W Rumsey, Case Lorance, Max Jackson, et al.
Clinical and Translational Science
|
June 1, 2022
Safety, pharmacokinetics and target engagement of novel RIPK1 inhibitor SAR443060 (DNL747) for neurodegenerative disorders: Randomized, placebo-controlled, double-blind phase I/Ib studies in healthy subjects and patients
Maurits F J M Vissers, Jules A A C Heuberger, Geert Jan Groeneveld, et al.
Page
of 5